Scientific News Boston Scientific Resumes Farapulse Pulsed Field Ablation Study In First Line Afib
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Scientific News Boston Scientific Resumes Farapulse Pulsed Field Ablation Study In First Line Afib is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
Boston Scientific enrolls first patient in AFib mapping study using OptiMap, Farapulse
A Boston Scientific (NYSE: BSX) official announced the enrollment of the first patients in the OPTIMIZE randomized controlled clinical trial. Read More
Boston Scientific’s FARAPULSE PFA: Revolutionizing Cardiac Ablation
Boston Scientific’s FARAPULSE Pulsed Field Ablation (PFA) system is making waves in how doctors treat irregular heart ... Read More
Boston Scientific Sustains EP Momentum in Q3: Is More Upside Ahead?
Boston Scientific’s BSX Electrophysiology (“EP”) sales surged 63% in the third quarter of 2025, reflecting continued share gains in the overall EP market. FARAPULSE, the company’s Pulsed Field ... Read More
Boston Scientific reports outcomes from Farapulse and Farapoint trial
Boston Scientific has reported positive 12-month primary endpoint outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse pulsed field ablation (PFA) system and Farapoint PFA ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus